Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct 25:5:34.
doi: 10.21037/tbcr-24-41. eCollection 2024.

Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?

Caterina Gianni  1 , Eleonora Nicolò  2 , Massimo Cristofanilli  2
Affiliations
Editorial

Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?

Caterina Gianni et al. Transl Breast Cancer Res. .
No abstract available

Keywords: CDK4/6 inhibitors; early breast cancer (EBC); hormone receptor positive (HR+); ribociclib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tbcr.amegroups.org/article/view/10.21037/tbcr-24-41/coif). M.C. serves as an unpaid editorial board member of Translational Breast Cancer Research from April 2023 to March 2025. M.C. reports personal fees from Lilly, Sermonix, Data Genomics, Foundation Medicine, Guardant Health, Celcuity, Iylon, and Ellipses and grants and personal fees from Pfizer, AZ and Menarini, all outside the submitted work. E.N. is supported by an American-Italian Cancer Foundation Post-Doctoral Research Fellowship. The other author has no conflicts of interest to declare.

Comment on

  • Ribociclib plus Endocrine Therapy in Early Breast Cancer.
    Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Ruiz-Borrego M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Afenjar K, Fresco R, Severin I, Ji Y, Ghaznawi F, Li Z, Zarate JP, Chakravartty A, Taran T, Hortobagyi G. Slamon D, et al. N Engl J Med. 2024 Mar 21;390(12):1080-1091. doi: 10.1056/NEJMoa2305488. N Engl J Med. 2024. PMID: 38507751 Clinical Trial.

Similar articles

See all similar articles

References

    1. Noone AM, Cronin KA, Altekruse SF, et al. Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992-2013. Cancer Epidemiol Biomarkers Prev 2017;26:632-41. 10.1158/1055-9965.EPI-16-0520 - DOI - PMC - PubMed
    1. Pan H, Gray R, Braybrooke J, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 2017;377:1836-46. 10.1056/NEJMoa1701830 - DOI - PMC - PubMed
    1. Gombos A, Goncalves A, Curigliano G, et al. How I treat endocrine-dependent metastatic breast cancer. ESMO Open 2023;8:100882. 10.1016/j.esmoop.2023.100882 - DOI - PMC - PubMed
    1. Johnston SRD, Toi M, O'Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023;24:77-90. 10.1016/S1470-2045(22)00694-5 - DOI - PMC - PubMed
    1. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med 2024;390:1080-91. 10.1056/NEJMoa2305488 - DOI - PubMed

LinkOut - more resources